Human tissue developer Humacyte agrees to SPAC merger to go public reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Humacyte Inc, a developer of universally implantable bioengineered human tissues and organs, has agreed a deal to go public through a merger with blank-check acquisition company Alpha Healthcare Acquisition Corp, according to people familiar with the matter.
Humacyte Set to Go Public, Raise $175 Million from Top-tier Investors
Durham-based Humacyte, a regenerative medicine company that received start-up support from the North Carolina Biotechnology Center 15 years ago, is going public in a novel deal that will give it a market capitalization of $1.1 billion.
Humacyte and Alpha Healthcare Acquisition Corp., a special purpose acquisition company (SPAC) based in New York, have signed a business-combination agreement to take Humacyte public, along with a $175M PIPE financing agreement.
“We are very pleased to have support from top-tier investors and access to the U.S. capital markets following the closing of this proposed transaction, which will leave Humacyte well-capitalized to provide first-in-class therapies to treat several life-threatening diseases,” Laura Niklason, M.D., Ph.D., founder and chief executive officer of Humacyte, said in a prepared statement.
DURHAM - Special Purpose Acquisition Companies (SPACs), the hottest financial craze to hit Wall Street for taking companies public, is hitting the Triangle with
Human tissue developer Humacyte nears SPAC deal to go public - sources reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.